Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (381)	1/25/2002 1:53:07 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

DGI has a profile in the new issue of Genetic Engineering News, "Genomics and Proteomics: Technologies and Deals" on page 40. DGI BioTechnologies (Edison, NJ) launched Proteome Panning, a proteome mining technology that has reportedly led to the identification of DGI-3, a new anti-cancer target. Proteome Panning allows the mining of DGI's RAPIDLIB random surrogate peptide libraries. A key attribute of their procedure is its simultaneous isolation and pairing of regulatory peptides or surrogates with the majority of the proteins contained within a proteome, according to the company. Surrogate peptides isolated in the Proteome Panning process are then available, first, to identify the natural partner and protein network for the target protein and, second, to regulate its activity in model systems to complete target validation. The overall process, referred to as Phenogenix, feeds into DGI's Diogenesis platform that searches for small molecule drug leads.